Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether serious graft versus host disease which is not
well controlled with steroid treatment can be controlled with therapy with both daclizumab
and infliximab. We hypothesize that a combination of daclizumab and infliximab will more
effectively treat graft versus host disease than therapy with a single drug. The study also
looks at whether chronic graft versus host disease develops, and survival at 6 and 9 months
post-treatment.